- CA$130.80m
- CA$170.26m
- $55.50m
Brief: Hls Therapeutics Establishes Automatic Share Purchase Plan
Brief: Saladax Biomedical And Hls Therapeutics Strengthen Partnership With An Exclusive Distribution Agreement For Canada
Brief: HLS Therapeutics Announces Q3 Fiscal 2021 Financial Results
Brief: HLS Therapeutics Announces Promotional Agreement With Pfizer For Vascepa
Brief: HLS Therapeutics Announces Second Quarter Fiscal 2021 Financial Results
Brief: Hls Therapeutics Reports Qtrly Loss Per Share $0.15
Brief: HLS Therapeutics Announces That Icosapent Ethyl (Vascepa®) Is Included In The 2021 Canadian Cardiovascular Society (CCS) Guidelines For The Management Of Dyslipidemia For The Prevention Of Cardiovascular Disease In Adults
Canada Research Roundup: Calian Group, Centerra Gold, Trulieve Cannabis
Brief: HLS Therapeutics Announces Q4 2020 Financial Results
Brief: HLS Says Private Payer Health Plan Coverage In Canada For Vascepa Expected To Reach Over 80% By Feb. End
Brief: Hls Therapeutics Announces Update On Health Canada Filings For Mycare And Trinomia
Brief: Hls Therapeutics Reports Efficacy And Safety Results From Pilot Study Treating Covid-19 Infected Outpatients With Vascepa®
Brief: HLS Therapeutics Establishes Automatic Share Purchase Plan
HLS Therapeutics: Up after Health Canada approves Schizophrenia treatment
Brief: HLS Therapeutics Announces Health Canada Approval Of Perseris For The Treatment Of Schizophrenia
Brief: Vascepa Found To Significantly Reduce Ischemic Events In Patients With Prior Coronary Artery Bypass Grafting Procedures
Brief: HLS Therapeutics Inc Reports Q3 Net Loss $0.05 Per Common Share
Brief: HLS Therapeutics Comments On U.S. Court Of Appeals Decision In Amarin Patent Litigation
Brief: HLS Says Vascepa Reported To Reduce Coronary Plaque In Evaporate Study Final Results